Findings on Adverse Drug Reactions Detailed by Investigators at University of California Los Angeles (UCLA) (Practical Guidance On [177lu]Lu-psma-617 Treatment, Including Radiation Safety, Adverse Event Monitoring, and Patient Counseling).

A recent study conducted at the University of California Los Angeles (UCLA) provides practical guidance for nurses working with the prostatespecific membrane antigen (PSMA)-targeted radioligand therapy [177Lu]Lu-PSMA-617. The therapy is used in the treatment of metastatic castration-resistant prostate cancer. The study emphasizes the role of nurses in managing radiation safety, monitoring adverse events, and counseling patients receiving this therapy. Nurses play a crucial role in coordinating safe care for patients by facilitating communication among physicians, managing logistics, monitoring for adverse events, and providing education and counseling throughout treatment. The research was supported by Novartis and has been peer-reviewed. [Extracted from the article]

Copyright of Drug Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)